Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials

Abstract

ObjectivesTo systematically review the efficacy and safety of anti-inflammatory agents for patients with major depressive disorders.MethodsWe searched the literature to identify potentially relevant randomised controlled trials (RCTs) up to 1 January 2019. The primary outcome was efficacy, measured by mean changes in depression score from baseline to endpoint. Secondary outcomes included response and remission rates and quality of life (QoL). Safety was evaluated by incidence of classified adverse events. Heterogeneity was examined using the I2 and Q statistic. Pooled standard mean differences (SMDs) and risk ratios (RRs) were calculated. Subgroup meta-analyses were conducted based on type of treatment, type of anti-inflammatory agents, sex, sponsor type and quality of studies.ResultsThirty RCTs with 1610 participants were included in the quantitative analysis. The overall analysis pooling from 26 of the RCTs suggested that anti-inflammatory agents reduced depressive symptoms (SMD −0.55, 95% CI −0.75 to −0.35, I2=71%) compared with placebo. Higher response (RR 1.52, 95% CI 1.30 to 1.79, I2=29%) and remission rates (RR 1.79, 95% CI 1.29 to 2.49, I2=41%) were seen in the group receiving anti-inflammatory agents than in those receiving placebo. Subgroup analysis showed a greater reduction in symptom severity in both the monotherapy and adjunctive treatment groups. Subgroup analysis of non-steroidal anti-inflammatory drugs, omega-3 fatty acids, statins and minocyclines, respectively, disclosed significant antidepressant effects for major depressive disorder (MDD). For women-only trials, no difference in changes of depression severity was found between groups. Subanalysis stratified by sponsor type and study quality led to the same outcomes in favour of anti-inflammatory agents in both subgroups. Changes of QoL showed no difference between the groups. Gastrointestinal events were the only significant differences between groups in the treatment periods.ConclusionsResults of this systematic review suggest that anti-inflammatory agents play an antidepressant role in patients with MDD and are reasonably safe.

Aspirin and other non-steroidal anti-inflammatory drugs and depression, anxiety, and stress-related disorders following a cancer diagnosis: a nationwide register-based cohort study

“…In contrast, although non-aspirin NSAIDs have mixed selectivity, they are mostly selective for COX-2 inhibition or non-selective, possibly leading to the observed harmful effect of non-aspirin NSAIDs on these psychiatric disorders. This was however partly inconsistent with the findings of a recent meta-analysis that found celecoxib to have an antidepressant effect when added to traditional antidepressants [24]. One possible explanation for the contradictory findings might be the fact that we studied newly onset depression, anxiety, and stress-related disorders after cancer diagnosis whereas Bai et al studied the treatment effort on prevalent depression [24].…”

Major Depressive Disorder Is Associated With Differential Expression of Innate Immune and Neutrophil-Related Gene Networks in Peripheral Blood: A Quantitative Review of Whole-Genome Transcriptional Data From Case-Control Studies

“…The evidence supporting this hypothesis has motivated a search for biomarkers of immune status that could be used to stratify MDD cases and to predict therapeutic response to anti-inflammatory drugs (2,4). Anti-inflammatory drugs have been associated with antidepressant effects in clinical trials for depression (5), in planned post hoc analysis of a subgroup of patients with MDD defined by a blood protein biomarker (6), and in clinical trials for arthritis and other systemic inflammatory or autoimmune disorders often associated with comorbid depression (7)(8)(9). It is already clear that to optimize the potential of anti-inflammatory interventions for depressive symptoms, new therapeutics must be precisely guided by development of immune biomarkers and companion diagnostics (4).…”

Rheumatoid Arthritis: The Impact of Mental Health on Disease: A Narrative Review

“…A systematic review of 30 randomised controlled trials (RCTs) showed that NSAIDs alleviated symptoms of depression [standard mean difference (SMD) -0.55, 95% CI -0.75 to -0.35] compared to the placebo arm [77]. A negative association between long-term NSAID use and depression [HR (95% CI): 0.20 (0.04-0.87)] but a non-specific statistical correlation on repeated testing is seen [78].…”